Saga Continues: Roche's Tamiflu No Better Than Tylenol At "Fighting Flu"

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Researchers who have fought for years to get full data on Roche's flu medicine Tamiflu said on Thursday that governments who stockpile it are wasting billions of dollars on a drug whose effectiveness is in doubt.

In a review of trial data on Tamiflu, and on GlaxoSmithKline's flu drug Relenza, scientists from the respected research network the Cochrane Review said that while the medicines can shorten flu symptoms by around half a day, there is no good evidence behind claims they cut hospital admissions or lessen complications of the disease.

Help employers find you! Check out all the jobs and post your resume.

Back to news